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Abstract
Background: Timely access to antiretroviral therapy is a key to controlling HIV infection. Late diagnosis and 
presentation to care diminish the benefits of antiretrovirals and increase risk of transmission. We aimed to identify late 
presenters in patients sent for first CD4 T cell count after HIV diagnosis, for therapy initiation evaluation. Further we 
aimed at identifying patient factors associated with higher risk of late presentation.
Methods: Retrospective data collection and analysis was done for 3680 subjects visiting the laboratory for CD4 T cell 
counts between 2001 and 2007. We segregated the patients on basis of their CD4 T cell counts after first HIV diagnosis. 
Factors associated with risk of late presentation to CD4 T cell counts after HIV diagnosis were identified using univariate 
analysis, and the strength of association of individual factor was assessed by calculation of odds ratios.
Results: Of 3680 subjects, 2936 (83.37%) were defined as late presenters. Late testing varied among age groups, 
transmission categories, and gender. Males were twice as likely to present late as compared to females. We found 
significant positive association of heterosexual transmission route (p < 0.001), and older age groups of 45 years and 
above (p = 0.0004) to late presentation. Female sex, children below 14 years of age and sexual contact with HIV positive 
spouse were associated with significantly lower risks to presenting late. Intravenous drug users were also associated 
with lower risks of late presentation, in comparison to heterosexual transmission route.
Conclusions: The study identifies HIV infected population groups at a higher risk of late presentation to care and 
treatment. The risk factors identified to be associated with late presentation should be utilised in formulating targeted 
public health interventions in order to improve early HIV diagnosis.
Background
AIDS is a dreaded disease, as even with recent advances
in the field of medicine and public health, no effective
vaccine or drug therapy is available to completely elimi-
nate the infection. During the natural course of HIV
infection, there is a progressive loss of CD4 T cells; the
rate of this loss being variable in patients, but averaging
around 60-100 cells/uL per year [1-3]. This drop in CD4
T cells leads to a severely immunocompromised state in
the infected host. Thereupon, a reduction in CD4 T cells
to below 200 cells/uL makes the host highly susceptible to
opportunistic infections and increases overall AIDS
related morbidity and mortality. It is universally docu-
mented that in the absence of effective antiretroviral
therapy, most people infected with HIV will progress to
AIDS in approximately ten years, with this period varying
from patient to patient based on host and viral factors [4].
Introduction of highly effective antiretroviral therapy
(HAART) has substantially improved patient prognosis
over the past decade [5,6]. Testing, diagnosis, and medi-
cal care soon after HIV infection and before developing
opportunistic infections and other AIDS defining illness
and clinical AIDS, can prevent illness, improve survival,
and reduce transmission. However, patients receiving
HIV diagnosis late in the course of infection are usually
more severely immunocompromised and are more likely
to present with co-morbidities like tuberculosis, and have
short-term mortality [7]. Delay in diagnosis is significant
to both disease prognosis at patient level and transmis-
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sion at community and public health level. An early diag-
nosis provides opportunities of reducing or halting
further transmission due to changes in risk behaviour [8].
Further, due to a higher viral burden in these patients, the
likelihood of transmission from these patients is also very
high compared to individuals diagnosed early in the
course of infection. Early diagnosis and immediate initia-
tion of therapy are essential components for the success
of HIV control and prevention programs.
Recent data indicates that early initiation of HAART is
advantageous when opportunistic infections are present
[9], as the overall mortality is excessively high in patients
with very late HIV disease and opportunistic infections.
Delay in initiating therapy in these patients is associated
with increased risk of mortality. Also, Immune Reconsti-
tution Inflammatory Syndrome (IRIS) which is associated
with low CD4 T cell counts at baseline occurs at a higher
frequency in subjects with late HIV diagnosis [10]. The
present study was carried out at one of the nation's big-
gest tertiary care hospital, the All India Institute of Medi-
cal Sciences (AIIMS) located in Delhi, the national
capital. The hospital caters to patients basically from
Delhi and the surrounding national capital region, which
includes Punjab, Chandigarh, Uttar Pradesh, Uttaranchal,
Uttarakhand, etc. However, it being the nation's premier
medical institute, we see influx of patients from most
states of India. In the present study, we aimed at assessing
the immunological profile of HIV infected Indian
patients at the time of first CD4 T cell count testing, and
to identify late presenters based on these counts. Also, we
examined proportion of subjects with higher CD4 T cell
counts, but with clinical complications related to HIV
disease, and thus being in immediate need of HAART ini-
tiation. Further, we try to identify factors which make an
individual more susceptible to being a late presenter to
HIV diagnosis and care.
Methods
The HIV scenario
India, with 2.27 million people living with HIV/AIDS and
a disease prevalence of 0.29% (2008-09), accounts for
roughly half of Asia's HIV prevalence. New Delhi, the
area where the study was conducted, is a low prevalence
state. However, being the nation's capital, the state sees a
huge influx of immigrants and truckers, thereby increas-
ing the high risk population. Most of the infections occur
through the heterosexual route, though the major trans-
mission route in north-eastern India is injection drug use.
The first phase National AIDS Control Programme
(NACP) was launched in 1992 with the objective of slow-
ing down the HIV infections in order to reduce the mor-
bidity, mortality and impact of HIV epidemic in the
country. Since then, the third phase of NACP has been
planned and implemented in 2007 with the objective of
halting and reversing the HIV epidemic in India over a
period of five years. The guiding principle of the NACP -
III objectives is provision of universal access to HIV pre-
vention, care, and support and treatment services. The
current HIV testing guidelines states client initiated test-
ing, except in case of pregnant females in which case HIV
testing is provider initiated. HIV treatment and monitor-
ing is universally accessible and free of cost at NACO des-
ignated clinics, and one such clinic is housed in the
AIIMS, which is the study's focus. The institute's HIV
division consists of an Integrated Counselling and Testing
Centre, in addition to a CD4 monitoring laboratory and
treatment clinic, all funded and supported by the national
program and NACO. The CD4 monitoring laboratory at
AIIMS, is housed in the Microbiology department, and
provides the monitoring services to all patients referred
to it through various OPDs, wards, and specialty clinics at
AIIMS providing HIV treatment and care.
Study subjects
This is a retrospective cross sectional study of all individ-
uals coming for CD4 testing for the first time after HIV
diagnosis (usually within a week of positive HIV serodi-
agnosis), to the CD4 testing laboratory at the Department
of Microbiology, All India Institute of Medical Sciences.
Subjects included 3,680 HAART naïve individuals with a
confirmed diagnosis of HIV with or without clinical
symptoms, coming to the laboratory between 2001 and
2007. Subjects on antiretroviral therapy at the time of
first visit to the laboratory were excluded from the pres-
ent study analysis. Similarly, subjects with a positive HIV
diagnosis more than one month before entering the HIV
care services at AIIMS were also excluded from the study
in order to control for the time since first HIV diagnosis.
The All India Institute of Medical Sciences Institute Eth-
ics Committee (AIIMS IEC) approved routine HIV diag-
nosis and CD4 testing.
Criteria for categorization as "late presenters to care"
For data analysis, as made classically all subjects with
CD4 T+ cell count below 200 cells/uL were classified as
'late presenters to care". Subjects were also stratified into
late and very late presenters depending on their CD4 T
cell counts being below 200 cells/uL and below 50 cells/
uL respectively. Further, subjects with CD4 T cell counts
above 200 cells/uL but with chronic clinical symptoms
like fever, diarrhoea, weight loss etc, were also included in
the category of late presenters to care and in need of
immediate start of HAART.
Data collection
Laboratory CD4 test subject database was accessed to
obtain following patient characteristics: age, sex, date of
CD4 testing, HIV transmission route as reported by the
patient, and clinical classification of patients on presenceMojumdar et al. BMC Public Health 2010, 10:416
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or absence of symptoms. Presence of TB, both pulmonary
and extrapulmonary, and Sexually Transmitted Diseases
(STDs) were also recorded.
Statistical analysis
Medians were calculated for study variable: age, CD4 T
cell counts, etc. Univariate regression analysis was per-
formed to identify patient factors which varied among
late presenters and non-late presenters. Multinomial
logistic regression analysis was performed to identify
independently associated patient factors with risk of pre-
senting late for HIV related treatment and care. Confi-
dence intervals at 95% level of confidence were calculated
for each associated factor. A p value of 0.05 or less was
considered significant.
Results
During 2001-2007, a total of 4,260 patients were tested
for CD4 T cell counts at the laboratory. Of these subjects,
3,680 subjects coming for HAART initiation evaluation
were retrospectively included in the study, excluding sub-
jects coming for follow-up visit or subjects already on
antiretroviral therapy at the time of first visit to labora-
tory. Patient characteristics according to CD4 T cell
counts is summarized in Table 1.The study subjects were
primarily males (2,598, 70.6%) aged between 25-44 years
(2,661, 72.36%) reporting heterosexual promiscuity as the
mode of HIV acquisition (1,475, 40.1%).
Majority of subjects presented with one or more AIDS
related and/or AIDS defining illnesses [11,12] at the time
of first CD4 T cell count (3,068, 83.4%). Among these, 529
(14.4% of total) subjects had pulmonary or extrapulmo-
nary TB, 102 (2.8%) had sexually transmitted infections at
the time of testing, and 564 subjects (15.3%) had at least
one AIDS defining illness.
The study group had a median CD4 T cell count of 242
cells/uL. Males had a lower median CD4 T cell count (207
cells/uL) as compared to females (243 cells/uL) with this
difference being statistically significant (p < 0.001). Of the
total study population, 2,113 (57.4%) had CD4 T cell
counts more than 200 cells/uL, 1,214 (33%) had CD4 T
cell count below 200 cells/uL, and 353 (9.6%) had less
than 50 CD4 T cells/uL. Patient characteristics according
to CD4 T cell counts are summarised in Table 2. Six hun-
dred and twelve (612) subjects with CD4 T cell counts
greater than 200 cells/uL, 120 subjects with less than 200
cells/uL, and 13 subjects with less than 50 CD4 T cells/uL
were asymptomatic at the time of CD4 test.
Subjects with less than 200 CD4 T cells/uL with (n =
1086) or without clinical symptoms (n = 120), and sub-
jects with clinical HIV infection irrespective of CD4 T
cell counts (1509), were together termed as "late present-
ers to care". Further, subjects with less than 50 CD4 T
cells/uL were termed "very late presenters", of which 340
Table 1: Study subject characteristics
Characteristics Number Percentage (%)
Year of testing
2001 275 7.5
2002 495 13.4
2003 457 12.4
2004 612 16.6
2005 535 14.5
2006 767 20.8
2007 539 14.6
Sex
Male 2598 70.6
Female 1082 29.4
Age Group
0-14 years 198 5.4
15-24 years 398 10.8
25-34 years 1612 43.8
35-44 years 1049 28.5
45 years & above 423 11.5
Transmission route
Heterosexual 1475 40.1
HIV+ spouse 783 21.3
Parent to child 133 3.6
Transfusion recipient 428 11.6
IVDU 43 1.2Mojumdar et al. BMC Public Health 2010, 10:416
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subjects were symptomatic and 13 subjects did not have
any clinical symptoms. Four hundred and seventy three
(473) late presenters (17.4% of 2723 late presenters) and
91 very late presenters (26.5%, of 343 very late presenters)
had clinically defined AIDS at the time of first presenting
to the laboratory.
Univariate analysis was performed for association
between patient characteristics and late presentation,
summarised in Table 2. Significant differences in propor-
tion of late presenters were recorded among subjects
reporting different modes of disease acquisition, with
highest late presentation seen in subjects reporting het-
erosexual promiscuity. Frequency of late presenters was
highest in males and age group 25-34 years, with all above
differences in proportion being statistically significant (p
< 0.001).
Multinomial logistic regression analysis was carried out
to identify patient factors independently associated with
late and very late presentation to care. In this analysis we
found that females were at a significantly lower risk to
present late or very late for CD4 testing as compared to
their male counterparts (late presentation: OR 0.49; 95%
CI 0.41 - 0.54, very late presentation: OR0.21; 95% CI 0.15
- 0.30). Similarly age groups 35-44 years (late presenta-
tion: OR 1.72; 95% CI 1.39 - 2.12, very late presentation:
OR 2.78; 95% CI 2.07 - 3.72), and age group of 45 years
and above (late presentation: OR 1.77; 95% CI 1.28 - 2.44,
very late presentation: OR 1.76; 95% CI 1.13 - 2.74) were
associated with higher frequency of late presentation.
On analysing various transmission routes reported by
subjects for their association with propensity for late pre-
sentation to care, transfusion of blood and blood prod-
ucts, homosexual transmission, occupational exposure
and those unaware or unwilling to disclose probable
route of HIV acquisition, were all found to increase the
risk of late presentation. Further we observed that female
sex, age at presentation less than 25, mother to child
route of transmission, HIV transmission through sexual
contact with infected spouse, and intravenous drug
abuse, were all associated with decreased chances of
delayed or late presentation to care with most associa-
tions statistically significant (Table 3).
Discussion
Late presentation with low baseline CD4 T cell counts
and presence of AIDS defining and/or AIDS associated
symptoms is the strongest prognostic marker for early
mortality in both low and high income countries. Gener-
ally late testing and presentation to HIV care centres and
programs is a result of diagnostic testing as a conse-
quence of symptoms, while earlier diagnosis is more typi-
cal of patient self-request for testing, self-perceived risk,
or universal screening [6]. An alarmingly high proportion
of HIV infected individuals are reported to present late
for care in developing countries like Sub-Saharan Africa,
South-East Asia, South America etc due to limited health
care access and health literacy [13,14]. Several studies
have identified delayed presentation to care, rather than a
late diagnosis, as cause of late initiation of HAART and
thus an underlying factor for poor prognosis [15].
In the present retrospective study, we set out to exam-
ine the level of late presentation to care of HIV infected
Indian individuals in a tertiary health care setting and to
identify the extent of immunosuppression in these sub-
jects along with presence of opportunistic infections. The
study population was mostly male of the reproductive age
group of 25-44 years thereby highlighting the most
affected population. The significantly low number of
females coming to the laboratory for CD4 T cell count
underscores the vast gap in health care uptake between
males and females. Heterosexual route of transmission
was the most common transmission route reported by
patients as a possible mode of disease acquisition as is
true for majority of HIV cases reported throughout India.
Several previous studies have reported various ways of
characterising late presenters to care. In our study,
patients having AIDS associated symptoms like chronic
diarrhoea, chronic fever, unexplained weight loss, oral
ulcers, etc and AIDS defining illnesses like pulmonary
and extra-pulmonary Tuberculosis (TB), STDs, Bacterial
diarrhoea, Pneumocystis carinii pneumonia, along with
patients having less than 200 CD4 T cells/uL of blood at
the time of first CD4 T cell count, were classified as late
Unsterile syringe use, 
Occupational exposure
32 0.9
MSM 4 0.1
Unknown, undisclosed 782 21.2
Symptoms
Asymptomatic 745 20.2
Symptomatic 2935 79.8
AIDS related/defining illnesses
TB 529 14.4
Sexually Transmitted 
Infections
102 2.8
Other AIDS defining illnesses 564 15.3
Table 1: Study subject characteristics (Continued)Mojumdar et al. BMC Public Health 2010, 10:416
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Table 2: Distribution of study subject characteristics based on CD4 T cell counts
Characteristics CD4 T cell counts (cells/uL) Overall p value
> 200 < 200 < 50
Sex
Male 1338 957 303 < 0.001
Female 775 257 50
Age Group
0-14 years 158 33 6
15-24 years 307 75 17
25-34 years 925 541 146 < 0.001
35-44 years 504 404 141
45 years & above 219 161 43
Transmission route
Heterosexual 779 535 165
HIV+ spouse 605 158 20
Parent to child 112 18 3
Transfusion recipient 212 167 49 < 0.001
IVDU 30 11 2
Unsterile syringe use, Occupational exposure 11 17 4
MSM 1 2 1
Unknown, undisclosed 363 310 109
Symptoms
Asymptomatic 612 120 13 < 0.001
Symptomatic 1509 1086 340Mojumdar et al. BMC Public Health 2010, 10:416
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presenters to care. We argued that the presence of
chronic illnesses like fever and diarrhoea etc though not
AIDS defining, are major pointers to raise suspicion of a
possible HIV infection. Further such symptoms would
highlight disease chronicity and thus should be labelled
as a missed opportunity for early diagnosis and care.
Nearly 80% of subjects were classified as late testers based
on above criteria. This proportion is very high compared
to other studies. As the setting for the study was one of
the nation's largest tertiary health care facilities, majority
of patients are referred here after efforts to treat them at
primary and secondary health care levels and also at pri-
vate settings. Therefore the proportion of sick and very
sick patients is usually higher at the laboratory as com-
pared to the clientele in private or secondary healthcare
settings, and can partly explain the huge proportions of
Table 3: Multinomial regression for association analysis of late presentation with patient factors
Patient Factor Late Presenters Very Late Presenters
OR (95% CI) p value OR (95% CI) p value
Sex
Male Reference
Female 0.49 (0.41-0.54) < 0.001 0.21 (0.15-0.30) < 0.001
Age Group
0-14 years 0.33 (0.23-0.5) < 0.001 0.23 (0.1-0.56) 0.0005
15-24 years 0.40 (0.30-0.50) < 0.001 0.27 (0.15-0.5) < 0.001
25-34 years Reference
35-44 years 1.47 (1.26-1.73) < 0.001 2.34 (1.7-3.2) < 0.001
45 years & above 1.26 (1.02-1.56) 0.034 1.9 (1.2-3.04) 0.006
Transmission route
Heterosexual Reference
HIV+ spouse 0.32 (0.27-0.40) < 0.001 0.10 (0.05-0.16) < 0.001
Parent to child 0.21 (0.13-0.34) < 0.001 0.10 (0.03-0.35) < 0.001
Transfusion recipient 1.8 (1.4-2.3) < 0.001 0.92 (0.6-1.4) 0.72
IVDU 0.49 (0.24-0.95) 0.03 0.26 (0.05-1.2) 0.06
Unsterile syringe use, Occupational exposure 2.16 (1.03-4.5) 0.04 2.3 (0.42-12.8) 0.32
MSM 3.4 (0.35-32.73) 0.26 3.5 (0.14-85.7) 0.28
Unknown, undisclosed 1.3 (1.1-1.54) 0.003 1.08 (0.77-1.5) 0.6Mojumdar et al. BMC Public Health 2010, 10:416
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late presenters in our study. Also, our inclusion of chronic
symptoms associated with HIV infection in addition to
AIDS defining events and low CD4 T cell counts further
increased this already large number of late presenters. A
sizeable number of patients (15.4%) had CDC stage C
HIV infection, ie clinical AIDS. This high number of
AIDS cases at time of first presentation to care marks an
alarming trend, clearly showing the lack of knowledge,
and low risk perception of being possibly HIV infected
and warrants further and renewed emphasis on health lit-
eracy.
Of all subjects studied, 14.4% had a pulmonary or extra-
pulmonary TB event at first time presentation to care.
Management of TB in late presenters with CD4 T cell
counts less than 200 cells/mL is a challenge due to an
increased risk of developing IRIS and additive drug toxic-
ities and interactions resulting from antimycobacterial
t h e r a p y .  T r e a t m e n t  i n  c a s e  o f  s u s p e c t e d  I R I S  i n v o l v e s
close monitoring and symptomatic administration of ste-
roids
At the time of first CD4 T cell count, 33% of subjects
had a CD4 T cell count below 200 cells/uL with 9.5% sub-
jects having CD4 T cell count below 50 cells/uL. This
h ug e  n u mbe r  of  im m u noc o m pr om ised pa t ie n ts  a t  fir s t
visit comprises subjects in need of immediate HAART
initiation. Further when segregated on symptoms, 120
patients with CD4 T cell counts less that 200 cells/uL
were found to be asymptomatic. As a sizeable part of the
study population were ones who visited the laboratory
before government of India roll out of free public sector
ART and free CD4 testing facilities for HIV infected
patients, many subjects without any apparent HIV related
s y m p t o m s  w o u l d  h a v e  b e e n  m i s s e d  f o r  i n i t i a t i o n  o f
HAART . Further we observed in our study population,
presence of patients with CD4 T cell counts well above
200 cells/uL and with chronic HIV associated symptoms
without any AIDS defining illness. Treatment strategy for
these patients is not clear in the currently available HIV-1
infection treatment guidelines, and thus most of them
just get symptomatic treatment instead of initiation of
HAART, thereby limiting the beneficial aspect of early
HAART initiation. Men had a lower CD4 T cell count at
first presentation to care for HAART evaluation as com-
pared to females, which is consistent with previous study
results. This can be attributed to the proportionately low
utilization of health care facilities by men as compared to
women.
In order to identify patient factors associated with late
presentation to care, we performed multinomial logistic
regression analysis to check the strength of association of
each factor independently with late and very late presen-
tation events. The factors associated with a risk of
delayed presentation to care as uncovered in present
study are consistent with results in other such studies
[16-19]. Heterosexual males were more at risk of being
late presenters as compared to females. The lower pro-
portion of females being late presenters can be attributed
to a higher uptake of Voluntary Counseling and Testing
services by the females as part of routine health care ser-
vices during pregnancy. Further females get tested soon
after their spouse test HIV positive; thereby being tested
at a much earlier stage of infection than their male coun-
terparts, who generally get tested on developing symp-
toms. Also, self perception of illness and need to access
h e a l t h  c a r e  i s  m o r e  i n  f e m a l e s  a s  c o m p a r e d  t o  m a l e s,
which is highlighted in an almost double chance of late
presentation in males [20,21]. Children diagnosed HIV
positive had a minimal risk of late presentation. This is
largely due to screening of pregnant females and provi-
sion of testing and treatment opportunities to children
born to affected mothers.
Association of higher age groups of 35-44 years ages 45
years and above seen in our study with late and very late
presentation to care has been emphasized in literature
[19,22,23]. Homosexual transmission route has been
reported to be associated with a lesser risk of late presen-
tation in previous studies [23,24]. However, in our study
we observed a very high risk of late presentation in this
group though the association was not statistically signifi-
cant. The lack of significance can be attributed to the very
s m a l l  n u m b e r  o f  s u b j e c t s  i n  t h i s  g r o u p .  H o w e v e r ,  w e
would like to mention here that homosexuality was
termed illegal in India till very recently and thus the stig-
matization of homosexual relations is very high. This is a
direct deterrent in utilization of HIV testing facilities and
thus multiplies many folds the chances of delayed presen-
tation. Injection drug users (IDUs) were another trans-
mission group found be at a lower risk of late
presentation in our data when compared to all other
reported transmission routes. Previous studies have iden-
tified IDUs as a population at high risk of late diagnosis
and care [23,25-27]. Identification of IDUs as a high risk
population for HIV acquisition and various government
and non-government bodies focusing on this population
in terms of routine HIV testing and regular health check-
ups could be the reason of lesser late presentation in
these individuals as a group.
Conclusion
In view of the results, there is a need for expanded rou-
tine testing of HIV infection with a stronger focus on
men who are observed as most vulnerable population for
late presentation. Also, emphasis should be given to test-
ing for HIV in higher age group subjects as they are also
more likely to be late presenters. The increased propor-
tion of late presenters highlights the delay in treatment to
these individuals, indicating the need to develop national
level strategies effective in promoting early diagnosis andMojumdar et al. BMC Public Health 2010, 10:416
http://www.biomedcentral.com/1471-2458/10/416
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of HIV infection in order to increase the impact of uni-
versal access HAART. In view of the public health impli-
cation of early HIV diagnosis for reducing HIV
transmission and preventing late presentation, HIV test-
ing should be more frequently prescribed in all health
care settings.
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